Royalty Pharma to Present at Upcoming Investor Conferences
May 13, 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, May 13, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of May: RBC...
Royalty Pharma Reports First Quarter 2024 Results
May 09, 2024 07:00 ET
|
Royalty Pharma plc
Royalty Receipts growth of 14% driving Portfolio Receipts of $717 millionNet cash provided by operating activities of $665 millionFull year 2024 guidance confirmed: Portfolio Receipts expected to be...
Royalty Pharma to Acquire Royalty Interest in Sanofi’s Frexalimab
May 09, 2024 06:45 ET
|
Royalty Pharma plc
Frexalimab is in Phase 3 development by Sanofi in multiple sclerosis with multi-blockbuster potential in a wide range of immune-mediated diseasesExpands Royalty Pharma’s development-stage portfolio to...
Royalty Pharma to Announce First Quarter 2024 Financial Results on May 9, 2024
April 19, 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, April 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2024 financial results on Thursday, May 9, 2024 before the U.S....
Royalty Pharma Declares Second Quarter 2024 Dividend
April 17, 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, April 17, 2024 (GLOBE NEWSWIRE) -- The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the second quarter of 2024 of $0.21 per Class A...
Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
February 28, 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in a fireside chat at TD Cowen’s 44th Annual Health Care Conference on March 5,...
Royalty Pharma Reports Q4 and Full Year 2023 Results
February 15, 2024 07:30 ET
|
Royalty Pharma plc
Portfolio Receipts of $736 million in Q4 2023 and $3,049 million for FY 2023Net cash provided by operating activities of $773 million in Q4 2023 and $2,988 million for FY 2023Announced transactions of...
Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
January 30, 2024 16:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 30, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its fourth quarter and full year 2023 financial results on Thursday, February 15,...
Royalty Pharma Announces Dividend Increase
January 19, 2024 08:15 ET
|
Royalty Pharma plc
NEW YORK, Jan. 19, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that its board of directors has declared a dividend for the first quarter of 2024 of $0.21 per Class A...
Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
January 08, 2024 07:00 ET
|
Royalty Pharma plc
2023 Portfolio Receipts expected to be approximately $3,050 million, exceeding the upper end of guidance rangeAnnounced transactions of $13 billion since 2020 expected to add approximately $1.2...